This week IP Today published an article by Pugatch Consilium Partner, Rachel Chu.
Looking at the race to develop the Ebola vaccine as well as other new medicines, the article draws a connection between investment in R&D, clinical trials and the protection of IPRs – all aimed at developing next generation healthcare technologies and medicines.
“Although increasing resources directed towards the health system is among the most obvious steps policymakers can take, one element often overlooked is the level of support toward research and development – including the protection afforded to intellectual property (IP) rights. In fact, strong IP protection is as important as health system capacity for attracting needed clinical trials – whether to prepare for future pandemics or to enable access to cutting edge cancer or diabetes treatments……A recent study by Pugatch Consilium suggests that a dedicated environment for innovation is actually just as, if not more, important as the health system capacity to clinical trial activity. Using regression analysis of data on 23 developed and developing countries, the study finds that clinical trial activity is better explained by the strength of IP protection (as well as the level of R&D expenditure) than by the number of hospital beds or investment in health. Just around 30% of clinical trial intensity can be explained by factors related to health system capacity and level of health spending, while over 40% can be explained by factors related to a pro-innovation culture – IP protection and R&D spending.
The article may be accessed using the following link:Share